Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: An update

International Journal of Women's Health

Volumn 1, Issue 1, 2009, Pages 11-20

  Messalli, Enrico M ^a   Scaffa, Cono ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Menopause; Osteoporosis; Raloxifene

Indexed keywords

ACOLBIFENE; ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; ARZOXIFENE; BAZEDOXIFENE; CENTCHROMAN; DROLOXIFENE; ESTROGEN; ESTROGEN RECEPTOR; IDOXIFENE; LASOFOXIFENE; LIPOPROTEIN; OSPEMIFENE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; RALOXIFENE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TAMOXIFEN;

BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; FEMALE; FLUID RETENTION; HOT FLUSH; HUMAN; LEG CRAMP; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SPINE FRACTURE; STROKE; VENOUS CIRCULATION; VENOUS THROMBOEMBOLISM;

EID: 77953454945     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/ijwh.s3894     Document Type: Review

References (102)

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94:646-650.
2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285,785-795.
3. Luisetto G, Zangari M, Tizian L, et al. Infl uence of aging and menopause in determining vertebral and distal forearm bone loss in adult healthy women. Bone Miner. 1993;22:9-25.
4. Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med. 1991;151:2026-2032.
5. Wark, JD. Osteoporosis: pathogenesis, diagnosis, prevention and management. Baillieres Clin Endocrinol Metab. 1993;7:151-181.
6. Hui SL, Wiske PS, Norton JA, Johnston CC Jr. A prospective study of change in bone mass with age in postmenopausal women. J Chronic Dis. 1982;35:715-725.
7. Riggs, BL, Khosla, S, Melton III LJ. A unitary model for involutional osteoporosis: estrogen defi ciency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 1998;13:763-773.
8. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726-1733.
9. Kanis JA, Johnell O; on behalf of the Committee of Scientifi c Advisors of the International Osteoporosis Foundation. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int. 2005;16:220-238.
10. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367:2010-2018.
11. Close P, Neuprez A, Reginster JY. Developments in the pharmaco-therapeutic management of osteoporosis. Expert Opin Pharmacother. 2006;7:1603-1615.
12. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48:271-287.
13. Deal CL, Draper MW. Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis - a clinical update on effi cacy and safety. Women's Health. 2006;2:199-210.
14. Riggs BL, Khosla S, Atkinson EJ, Dunstan CR, Melton III LJ. Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen defi ciency. Osteoporos Int. 2003;14:728-733.
15. Bord S, Ireland DC, Beavan SR, Compston JE. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone. 2003;32:136-141.
16. Oleksik AM, Duong T, Pliester N, Asma G, Popp-Snijders C, Lips P. Effects of the selective estrogen receptor modulator, raloxifene on the somatotropic axis insulin-glucose homeostasis. J Clin Endocrinol Metab. 2001;86:2763-2768.
17. Xing L, Boyce BF. Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun. 2005;328:709-720.
18. Million Women Study (MWS). Breast cancer and hormone replacement therapy in the Million Women study Collaborators. Lancet. 2003;302:419-427.
19. Writing group for the Women's Health Initiative (WHI) investigators. Risks and benefi ts of estrogen plus progestin in health postmenopausal: principal results from Women's Health Initiative Randomized Controlled Trial. JAMA. 2002;288:321-333.
20. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:701-712.
21. Siris E, Adachi JD, Lu Y, et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple outcomes of raloxifene evaluation. Osteoporos Int. 2002;13:907-913.
22. The North American Menopause Society (NAMS). Management of postmenopausal osteoporosis. Position statement. Menopause. 2002;9:84-101.
23. Riggs BL, Melton LJ. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res. 2002;171:11-14.
24. Riggs BL, Hartmann LC. Selective estrogen receptor modulatorsmechanism of actions and application to clinical practice. N Engl J Med. 2003;348:618-629.
25. Fuchs-Young R, Glasebrook AL, Short LL, et al. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann N Y Acad Sci. 1995;761:355-360.
26. Brzozowski AM, Pike ACW, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389:753-758.
27. Anzano MA, Peer CW, Smith JM, et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst. 1996;88:123-125.
28. Taranta A, Brama M, Teti A, et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone. 2002;30:368-376.
29. Cheung J, Mak YT, Papaioannou S, Evans BAJ, Fogelman I, Hampson G. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-βoestradiol and raloxifene. J Endocrinol. 2003;177;423-433.
30. Messalli EM, Mainini G, Scaffa C, et al. Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas. 2007;56:38-44.
31. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319.
32. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176.
33. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 1999;145: 527-538.
34. Lacey DL, Tan, HL, Lu J, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol. 2000;157:435-448.
35. Feng, X. RANKing intracellular signaling in osteoclasts. IUBMB Life. 2005;57:389-395.
36. Liao EY, Luo XH, Su X. Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. J Endocrinol Invest. 2002;25:785-790.
37. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-342.
38. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292:490-495.
39. Viereck V, Gründker C, Blaschke S, et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab. 2003; 88:4206-4213.
40. Delmas PD, Ensrud KE, Adachi JD, et al. Effi cacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: 4-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87:3609-3617.
41. Byrjalsen I, Leeming DJ, Qvist P, Christiansen C, Karsdal MA. Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int. 2008;19:339-348.
42. Johnston CC Jr, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med. 2000;160:3444-3450.
43. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA. 1999;282:637-645.
44. Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone. 2003;33:522-532.
45. Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Int Med. 2002;162:1140-1143.
46. Qu Y,Wong M, Thiebaud D, Stock JL. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and 6 months: a secondary analysis of the MORE trial. Curr Med Res Opin. 2005;21:1955-1959.
47. Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res. 2005;20:1514-1524.
48. Barrett-Connor E, Mosca L, Collins P, et al.; for the Raloxifene Use for The Heart (RUTH) trial investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125-137.
49. Ensrud KE, Stock JL, Barrett-Connor E, et al. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J Bone Miner Res. 2008;23:112-120.
50. Lufkin EG, Sarkar S, Kulkarni PM, et al. Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial. Current Medical Research and Opinion. 2004;20:351-357.
51. Recker D, Kendler C, Recknor T, et al. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone. 2007;40:843-851.
52. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148:197-213.
53. Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H. Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. Yonsei Med J. 2008;49:119-128.
54. Jolly EE, Bjarnason NH, Neven P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause. 2003;10:337-344.
55. Neele SJ, Evertz R, De Valk-De Roo G, Roos JC, Netelenbos JC. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone. 2002;30:599-603.
56. Briot K, Tremollieres F, Thomas T, Roux C; pour le comité scientifique du GRIO. How long should patients take medications for postmenopausal osteoporosis? Joint Bone Spine. 2007;74: 24-31.
57. Uusi-Rasi K, Beck TJ, Semanick LM, et al. Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. Osteoporos Int. 2006;17:575-586.
58. Cadarette SM, Katz JN, Brookhart MA, Sturmer T, Stedman MR. Solomon DH. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med. 2008;148:637-646.
59. Pelayo I, Haya J, De la Cruz JJ, et al. Raloxifene plus ossein-hydroxy-apatite compound versus raloxifene plus calcium carbonate to control bone loss in postmenopausal women: a randomized trial. Menopause. 2008;15(6):1132-1138.
60. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-1647.
61. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96:1751-1761.
62. Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL. Safety assessment of raloxifene over 8 years in a clinical trial setting. Curr Med Res Opin. 2005;21:1441-1452.
63. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727-2741.
64. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. J Am Med Assoc. 2006;295:2742-2751.
65. Freedman M, Martin JS, O'Gorman J, et al. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst. 2001;93:51-56.
66. Dowsett M, Bundred NJ, Decensi A, et al. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind placebo controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev. 2001;10:961-966.
67. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. J Am Med Assoc. 1999;281:2189-2197.
68. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat. 2001;65:125-134.
69. Burshell AL, Song J, Dowsett SA, et al. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis. Curr Med Res Opin. 2008;24:807-813.
70. Grady D, Cauley JA, Geiger MJ, et al; Raloxifene Use for The Heart Trial Investigators. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst. 2008;100:854-861.
71. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002;287:847-857.
72. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445-1451.
73. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2000;85:214-218.
74. Dayspring T, Qu Y, Keech C. Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia. Metabolism. 2006;55:972-979.
75. Nanetti L, Camilletti A, Francucci CM, et al. Role of raloxifene on platelet metabolism and plasma lipids. Eur J Clin Invest. 2008;38:117-125.
76. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
77. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
78. Colacurci N, Fornaro F, Cobellis L, et al. Raloxifene slows down the progression of intima-media thickness in postmenopausal women. Menopause. 2007;14:879-884.
79. Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: Multiple Outcomes of Raloxifene Evaluation. Obstet Gynecol. 2004;104:837-844.
80. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
81. Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost. 2008;99:338-342.
82. Blumenthal RS, Baranowski B, Dowsett SA. Cardiovascular effects of raloxifene: the arterial and venous systems. Am Heart J. 2004;147:783-789.
83. Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE; MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Am Soc Nephrol. 2008;19:1430-1438.
84. Komi J, Lankinen KS, DeGregorio M, et al. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab. 2006;24:314-318.
85. Stump AL, Kelley KW, Wensel TM. Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis. Ann Pharmacother. 2007;41:833-839.
86. Gennari L. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis. Drugs Today. 2006;42: 355-367.
87. Lee A, Radecki D, Wolter K, et al. Lasofoxifene phase 2 and phase 3 clinical trial design and strategy [abstract]. J Bone Miner Res. 2005;20: S1 M384
88. Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging. 2007;24:361-379.
89. Vogelvang TE, van der Mooren MJ, Mijatovic V, Kenemans P. Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women. Drugs. 2006;66:191-221.
90. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res. 2008;23:525-535.
91. Carranza-Lira S, Gooch AL, Saldivar N, Osterwalder MS. Climacteric symptom control after the addition of low-dose esterifi ed conjugated estrogens to raloxifene standard doses. Int J Fertil Womens Med. 2007;52:93-96.
92. Pinkerton JV, Dalkin AC. Combination therapy for treatment of osteoporosis: a review. Am J Obstet Gynecol. 2007;197:559-565.
93. Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging. 2007;24:37-55.
94. Pasion EG, Sivananthan SK, Kung AW, et al. Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women. J Bone Miner Metab. 2007;25: 105-113.
95. Michalska D, Stepan JJ, Basson BR, Pavo I. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2006;91:870-877.
96. Rosa J, Vanuga P, Payer J, Svobodník A. Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene). Vnitr Lek. 2008;54:217-9, 221-4.
97. Lippuner K. Medical treatment of vertebral osteoporosis. Eur Spine J. 2003;12 Suppl 2:S132-S141.
98. Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ. Risk-benefi t profi le for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J Bone Miner Res. 2004;19:1270-1275.
99. US Food and Drug Administration. EVISTA label. NDA no. 022042 approved on 09/13/2007.
100. Lee W-L, Chaob H-T, Cheng M-H, Wang P-H. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Maturitas. 2008;60:92-107.
101. Kanis JA, Burlet N, Cooper C, et al. on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;19: 399-428.
102. Jordan VC. SERMs: meeting the promise of multifunctional medicines. J Natl Cancer Inst. 2007;99:350-356.